# IDEAYA Biosciences, Inc.: overview

IDYA · Nasdaq · CIK 1676725 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/idya.md) · [Financials](/companies/idya/financials.md) · [Filings](/companies/idya/filings.md) · [Insiders](/companies/idya/insiders.md)

Latest reported revenue: [$8.9m](/filings/0001193125-26-332774.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 4, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-332774).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0](/filings/0000950170-24-120675.md) | [7.0 d](/filings/0001193125-26-054533.md) | not reported | not reported | [208](/filings/0001193125-25-264632.md) | [10.9 d](/filings/0001193125-26-054533.md) | [6.6](/filings/0001193125-26-206357.md) | [8.9](/filings/0001193125-26-332774.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | [(2059.1%) d](/filings/0001193125-26-054533.md) | not reported | not reported | [52.2%](/filings/0001193125-25-264632.md) | [(869.5%) d](/filings/0001193125-26-054533.md) | [(1654.6%)](/filings/0001193125-26-206357.md) | [(1380.7%)](/filings/0001193125-26-332774.md) |
| Net margin | % | not reported | [(1861.6%) d](/filings/0001193125-26-054533.md) | not reported | not reported | [57.4%](/filings/0001193125-25-264632.md) | [(765.7%) d](/filings/0001193125-26-054533.md) | [(1502.1%)](/filings/0001193125-26-206357.md) | [(1269.6%)](/filings/0001193125-26-332774.md) |
| Diluted EPS | $ per share | [(0.60)](/filings/0001193125-25-264632.md) | not reported | [(0.82)](/filings/0001193125-26-206357.md) | [(0.88)](/filings/0001193125-26-332774.md) | [1.33](/filings/0001193125-25-264632.md) | not reported | [(1.11)](/filings/0001193125-26-206357.md) | [(1.22)](/filings/0001193125-26-332774.md) |
| Free cash flow | $m | [(49.7) d](/filings/0001193125-25-264632.md) | [(123) d](/filings/0001193125-26-054533.md) | [(61.7)](/filings/0001193125-26-206357.md) | [(63.1) d](/filings/0001193125-26-332774.md) | [142 d](/filings/0001193125-25-264632.md) | [(90.8) d](/filings/0001193125-26-054533.md) | [(76.1)](/filings/0001193125-26-206357.md) | [(89.1) d](/filings/0001193125-26-332774.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [27.9](/filings/0000950170-24-017093.md) | [50.9](/filings/0000950170-25-022183.md) | [23.4](/filings/0001193125-26-054533.md) | [7.0](/filings/0001193125-26-054533.md) | [219](/filings/0001193125-26-054533.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(179.9%)](/filings/0000950170-24-017093.md) | [(122.7%)](/filings/0000950170-25-022183.md) | [(574.9%)](/filings/0001193125-26-054533.md) | [(4671.1%)](/filings/0001193125-26-054533.md) | [(72.8%)](/filings/0001193125-26-054533.md) |
| Net margin | % | [(178.1%)](/filings/0000950170-24-017093.md) | [(115.2%)](/filings/0000950170-25-022183.md) | [(483.0%)](/filings/0001193125-26-054533.md) | [(3921.1%)](/filings/0001193125-26-054533.md) | [(52.0%)](/filings/0001193125-26-054533.md) |
| Diluted EPS | $ per share | [(1.41)](/filings/0000950170-24-017093.md) | [(1.42)](/filings/0000950170-25-022183.md) | [(1.96)](/filings/0001193125-26-054533.md) | [(3.36)](/filings/0001193125-26-054533.md) | [(1.28)](/filings/0001193125-26-054533.md) |
| Free cash flow | $m | [(58.4)](/filings/0000950170-24-017093.md) | [(90.6)](/filings/0000950170-25-022183.md) | [(118)](/filings/0001193125-26-054533.md) | [(251)](/filings/0001193125-26-054533.md) | [(73.5)](/filings/0001193125-26-054533.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/idya/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $525.9m | 14,109,431 |  | Added +937,328 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $331.5m | 8,893,260 |  | Added +451,127 |
| [Jupiter Topco LLC](/funds/2146052.md) | 2026-06-30 | $319.7m | 8,579,881 |  | Not compared |
| [JANUS HENDERSON GROUP PLC](/funds/1274173.md) | 2026-03-31 | $242.0m | 7,265,253 |  | Not compared |
| [Capital Research Global Investors](/funds/1422848.md) | 2026-06-30 | $199.2m | 5,344,701 |  | Added +181,158 |
| [BAKER BROS. ADVISORS LP](/funds/1263508.md) | 2026-06-30 | $186.7m | 5,010,030 |  | Added +1,063,515 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $169.5m | 4,548,911 |  | Added +767,744 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $154.0m | 4,132,646 |  | Added +400,224 |
| [Logos Global Management LP](/funds/1792126.md) | 2026-06-30 | $111.8m | 3,000,000 |  | Reduced −450,000 |
| [ADAGE CAPITAL PARTNERS GP, L.L.C.](/funds/1165408.md) | 2026-06-30 | $101.2m | 2,715,391 |  | Reduced −108,109 |

## Recent filings

[All 496 filings](/companies/idya/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-04 | 20:05 ET | [10-Q](/filings/0001193125-26-332774.md) | Quarterly report, period 2026-06-30 | 0001193125-26-332774 |
| 2026-08-04 | 10:01 ET | [8-K](/filings/0001193125-26-331381.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-331381 |
| 2026-06-23 | 20:05 ET | [8-K](/filings/0001193125-26-279427.md) | 5.07 Shareholder vote results; 8.01 Other events | 0001193125-26-279427 |
| 2026-06-10 | 20:10 ET | [8-K](/filings/0001193125-26-265833.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-265833 |
| 2026-06-03 | 10:01 ET | [8-K](/filings/0001193125-26-254476.md) | 8.01 Other events | 0001193125-26-254476 |
| 2026-06-01 | 20:05 ET | [8-K](/filings/0001193125-26-251399.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-251399 |
| 2026-05-05 | 21:21 ET | [8-K](/filings/0001193125-26-206806.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-206806 |
| 2026-05-05 | 20:05 ET | [10-Q](/filings/0001193125-26-206357.md) | Quarterly report, period 2026-03-31 | 0001193125-26-206357 |
| 2026-05-05 | 10:05 ET | [8-K](/filings/0001193125-26-204944.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-204944 |
| 2026-04-29 | 20:05 ET | [DEF 14A](/filings/0001193125-26-191501.md) | Proxy statement, period 2026-06-16 | 0001193125-26-191501 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-054533.md), filed Feb 17, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/2a1fab32-7137-4f1e-9770-28303b62ad5d)

## About the filer

- CIK: 1676725
- Tickers: IDYA
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.